| Followers | 3805 |
| Posts | 244703 |
| Boards Moderated | 0 |
| Alias Born | 07/30/2007 |
Thursday, July 30, 2020 2:55:36 PM
ACHV Beyond The Short Squeeze
The fact of the matter is that while the short squeeze is driving attention for Achieve Life Sciences, the company represents a strong opportunity outside of the squeeze. It has to do with smoking.
Over the past decade or so, we’ve seen a big push to get smokers to quit smoking cigarettes. However, doing so is very difficult. In order to fight the addiction, smokers spend more than $21 billion annually on products that are designed to help them quit.
With that ACHV is working on a smoking cessation product known as cytisinicline, and has had some pretty strong success. In fact, about a month ago, the company released the results from an investigator-initiated study that compared cytisinicline to the top smoking cessation drug on the market, Chantix.
Importantly, cytisinicline outperformed Chantix, setting the stage for the company to push toward commercialization with a drug that represents a multi-billion dollar opportunity.
So, even without the short squeeze, the promise offered through cytisinicline suggests that you should be paying close attention to ACHV stock.
The fact of the matter is that while the short squeeze is driving attention for Achieve Life Sciences, the company represents a strong opportunity outside of the squeeze. It has to do with smoking.
Over the past decade or so, we’ve seen a big push to get smokers to quit smoking cigarettes. However, doing so is very difficult. In order to fight the addiction, smokers spend more than $21 billion annually on products that are designed to help them quit.
With that ACHV is working on a smoking cessation product known as cytisinicline, and has had some pretty strong success. In fact, about a month ago, the company released the results from an investigator-initiated study that compared cytisinicline to the top smoking cessation drug on the market, Chantix.
Importantly, cytisinicline outperformed Chantix, setting the stage for the company to push toward commercialization with a drug that represents a multi-billion dollar opportunity.
So, even without the short squeeze, the promise offered through cytisinicline suggests that you should be paying close attention to ACHV stock.
Recent ACHV News
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/25/2026 12:12:50 AM
- Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 04/24/2026 09:03:15 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 09:01:21 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/24/2026 08:57:11 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/24/2026 08:12:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 10:20:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 10:16:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/16/2026 08:47:39 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 04/16/2026 08:11:38 PM
- Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors • GlobeNewswire Inc. • 04/16/2026 12:57:06 PM
- Achieve Life Sciences Announces Up to $354 Million Private Placement • GlobeNewswire Inc. • 04/16/2026 12:53:49 PM
- Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Achieve Life Sciences Announces Publication in Nicotine & Tobacco Research Linking Cytisinicline's Receptor Selectivity to Low Nausea Rates and Favorable Tolerability • GlobeNewswire Inc. • 03/26/2026 12:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/24/2026 08:12:47 PM
- Achieve Life Sciences reports fourth-quarter results in line with expectations • IH Market News • 03/24/2026 12:37:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 11:05:07 AM
- Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 03/24/2026 11:00:00 AM
- Achieve Life Sciences to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on March 24, 2026 • GlobeNewswire Inc. • 03/17/2026 12:30:00 PM
- Achieve Life Sciences Presents Data at SRNT Demonstrating Successful Cessation in Smokers with Extensive Prior Treatment Exposure; and on Participant Experience in the ORCA-OL Study • GlobeNewswire Inc. • 03/04/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2026 09:09:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2026 09:08:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2026 09:07:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2026 09:06:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2026 09:05:03 PM
- Achieve Life Sciences Announced Granting of New Hire Inducement Awards • GlobeNewswire Inc. • 01/30/2026 09:05:00 PM
